This HTML5 document contains 49 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://dx.doi.org/10.1097/
n7http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q57567690
rdf:type
wikibase:Item
schema:description
наукова стаття, опублікована у вересні 2006 im September 2006 veröffentlichter wissenschaftlicher Artikel wetenschappelijk artikel article
p:P577
wds:Q57567690-853F02B1-3E73-4E24-AA64-3A8BD2C3672B
wdt:P577
2006-09-01T00:00:00Z
p:P407
wds:Q57567690-948E9AC2-680F-4D2B-BACE-D05143638A8C
wdt:P407
wd:Q1860
rdfs:label
Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children
skos:prefLabel
Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children
schema:name
Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children
p:P50
wds:Q57567690-75F760EC-69F7-4EC6-ADA5-4004CBA6A5C1 wds:Q57567690-785E6D10-3335-4773-A416-5B992469A7D5 wds:Q57567690-85C881CF-542C-440D-8AD4-849606BAAD4C wds:Q57567690-A9A55B38-D329-4C93-BE65-765B69C37AD1 wds:Q57567690-BF19BF27-91BB-413C-8697-C02468F83278 wds:Q57567690-214D5161-D289-42AB-B5A6-96A2B610056E wds:Q57567690-2B015644-9BCE-42ED-9606-DC9589A18F19 wds:Q57567690-4831A42C-356A-459A-8BAF-8232D87EFBE8
wdt:P50
wd:Q56743799 wd:Q42533864 wd:Q117234851 wd:Q117234855 wd:Q117234857 wd:Q42642662 wd:Q59104239 wd:Q56991981
p:P1476
wds:Q57567690-0AD59383-474F-4811-BEB8-D4C52BB02477
wdt:P1476
Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children
p:P304
wds:Q57567690-5A8A0FCF-4047-4467-9F11-878E9A8BC67F
wdt:P304
1893-1896
p:P31
wds:Q57567690-4A18DA60-F3F0-440E-9B61-678B2FF79761
wdt:P31
wd:Q13442814
p:P698
wds:Q57567690-15A1B499-2D01-44C6-8E14-7A6DC7440E93
wdtn:P698
n7:16954733
wdt:P698
16954733
p:P1433
wds:Q57567690-2CE597C8-9E7D-49AE-84A1-6AA3CD0C78D1
wdt:P1433
wd:Q4651863
p:P433
wds:Q57567690-155CAC11-5678-46CF-8605-AD509B269143
p:P478
wds:Q57567690-6F27281A-1180-41FB-BE8E-A37FA0856058
wdt:P433
14
wdt:P478
20
p:P356
wds:Q57567690-205C95D5-F0BC-4330-B1EB-AE36AB48E8D0
wdtn:P356
n9:01.AIDS.0000244211.33876.6F
wdt:P356
10.1097/01.AIDS.0000244211.33876.6F